Explore PMOS Research
Search 20,749 PMOS papers published between 2015 and 2025. Filter by research topic, country, year range, or co-investigated condition to find where the field is active — and where the gaps are.
Total citations
289,983
Peak year
2025(3,021 articles)
Avg citations / article
14
Publications per year
Topics
All research areas ⓘArticle mentionsA paper tagged with multiple topics counts once in each. The Overview uses fractional counting instead. See methodology.
Countries
All countries
Top journals
All filters
Top institutions
All filters
Where in the world is each topic being researched?
Toggle between Revealed Comparative Advantage (RCA), a specialisation index where values above 1.0 mean a country focuses on that topic more than average, and raw article counts.
| Hormones | Metabolic | Fertility | Epidemiol. | Pharma | Diagnos. | Genetics | Mental | Nutrition | Molecular | Inflamm. | Cell Bio | Lifestyle | Microbiome | Dermatol. | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| China | 1.0 | 0.9 | 1.1 | 0.9 | 1.1 | 0.7 | 1.5 | 0.4 | 0.7 | 1.9 | 1.1 | 2.1 | 0.5 | 1.4 | 0.2 |
| United States | 1.0 | 1.1 | 1.0 | 1.3 | 0.8 | 1.1 | 0.9 | 1.4 | 0.6 | 0.6 | 0.7 | 0.6 | 1.0 | 0.6 | 1.3 |
| India | 0.9 | 0.9 | 0.9 | 0.9 | 0.9 | 1.9 | 1.1 | 1.1 | 1.7 | 0.8 | 0.7 | 0.6 | 1.2 | 1.2 | 1.9 |
| Iran | 1.0 | 0.9 | 0.9 | 0.9 | 1.6 | 0.5 | 0.7 | 1.2 | 1.8 | 0.9 | 2.0 | 0.7 | 1.1 | 0.9 | 0.8 |
| Turkey | 1.2 | 1.2 | 0.8 | 0.4 | 0.4 | 1.4 | 0.5 | 1.0 | 1.0 | 0.6 | 1.7 | 0.5 | 0.4 | 1.3 | 1.4 |
| United Kingdom | 0.9 | 1.0 | 0.9 | 1.3 | 1.0 | 0.9 | 0.8 | 2.0 | 0.9 | 0.5 | 0.7 | 0.3 | 1.8 | 0.5 | 1.3 |
| Australia | 0.8 | 1.1 | 0.9 | 1.9 | 1.1 | 0.8 | 0.6 | 2.1 | 0.7 | 0.2 | 0.1 | 0.5 | 4.0 | 0.4 | 0.5 |
| Italy | 1.1 | 1.2 | 1.0 | 0.8 | 0.9 | 1.2 | 0.5 | 0.8 | 1.5 | 0.6 | 0.7 | 0.3 | 0.5 | 1.0 | 1.0 |
| Egypt | 1.0 | 0.8 | 1.9 | 0.4 | 1.7 | 0.8 | 0.4 | 0.6 | 1.1 | 0.6 | 1.0 | 0.5 | 0.3 | 0.3 | 2.2 |
| Poland | 1.3 | 1.4 | 0.5 | 0.6 | 0.4 | 0.8 | 0.6 | 1.2 | 0.8 | 0.6 | 1.2 | 0.4 | 1.1 | 1.7 | 1.6 |
Studies621–640 of 20,710
All studies
CRISPR as a Tool to Uncover Gene Function in Polycystic Ovary Syndrome: A Literature Review of Experimental Models Targeting Ovarian and Metabolic Genes
Importance of Lactate Dehydrogenase, Cortisol, Dopamine, Zinc, and Vitamin D3 in Iraqi Patients with Polycystic Ovary Syndrome
Therapeutic effects and potential mechanisms of caffeine on obese polycystic ovary syndrome: bioinformatic analysis and experimental validation
Gaps and opportunities in polycystic ovary syndrome care—a qualitative study
Diabetic complications in women with type 2 diabetes and polycystic ovary syndrome
Effect of probiotic-derived metabolites on hormonal and metabolic profiles in women with polycystic ovary syndrome: a systematic review and meta-analysis
Evaluating spironolactone monotherapy against combined treatment with metformin in rat PCOS model.
The impact of GABA and GABAergic pathway in polycystic ovary syndrome: a systematic review
Cannabidiol improves metabolic profiles and alleviates liver inflammation and fibrosis in conditions of androgenic obesity and polycystic ovary syndrome
Glucose-dependent insulinotropic peptide (GIP) suppresses androgen biosynthesis in PCOS mouse models and cellular systems.
PLK2 as a key regulator of glycolysis and immune dysregulation in polycystic ovary syndrome
Ovulation induction in anovulatory PCOS women.
Validity of administrative health data case definitions for identifying polycystic ovary syndrome: a systematic review and meta-analysis
Investigation of Inflammatory Markers in Patients with Polycystic Ovary Syndrome Receiving and Not Receiving Metformin Treatment
SIRT1 inhibits ferroptosis of granulosa cells in polycystic ovarian syndrome.
The prevalence of autoimmune thyroiditis is not increased in women with polycystic ovary syndrome after adjustment for family predisposition
Assessing Usability of Polycystic Ovary Syndrome (PCOS) Related Mobile Applications: A Multimethod Evaluation
Prepregnancy levels of antimüllerian hormone do not impact the perinatal outcomes in women with polycystic ovary syndrome
Differential cardiometabolic outcomes of leuprolide versus spironolactone in women with polycystic ovary syndrome
Adverse Cardiometabolic Outcomes in Men With Sisters With Polycystic Ovary Syndrome